Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.

[1]  Jun Yang,et al.  Proportion of different subtypes of stroke in China. , 2003, Stroke.

[2]  Jie Chen,et al.  [An epidemiological survey of atrial fibrillation in China]. , 2004, Zhonghua nei ke za zhi.

[3]  Changsheng Ma,et al.  Anticoagulation control in atrial fibrillation patients present to outpatient clinic of cardiology versus anticoagulant clinics. , 2005, Chinese medical journal.

[4]  Wansu Chen,et al.  Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[5]  D. Hu,et al.  Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. , 2008, Journal of the American College of Cardiology.

[6]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[7]  K. Okumura,et al.  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version , 2010 .

[8]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[9]  R. Investigators.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.

[10]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[11]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[12]  D. Hu,et al.  Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients , 2012, Journal of Thrombosis and Thrombolysis.

[13]  C. Sudlow,et al.  Epidemiology of stroke and its subtypes in Chinese vs white populations , 2013, Neurology.

[14]  S. Yusuf,et al.  Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation , 2013, Stroke.

[15]  J. Dou,et al.  [Towards better postoperative function management of endocrine gland]. , 2013, Zhonghua nei ke za zhi.

[16]  G. Breithardt,et al.  Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial , 2014, Stroke.

[17]  Jun Zhu,et al.  Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. , 2014, American heart journal.

[18]  B. Ahrén,et al.  Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. , 2014, Metabolism: clinical and experimental.